Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
 - EconoTimes)
NEW YORK, Dec. 20, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into NovoCure Limited (NVCR) (“NovoCure”). If you are a NovoCure shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770, email [email protected] or go to: http://www.scott-scott.com/cases/investigations/securities-fraud-litigation-3079-novocure-limited.html.
NovoCure develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (“TTFields”). NovoCure markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.
On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that “[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use.”
On this news, NovoCure’s stock fell from a July 27, 2016 price of $11.44 to a July 28, 2016 price of $8.09, a one-day decline of over 29%.
If you are a NovoCure shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at [email protected].
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.
CONTACT: Michael Burnett Scott+Scott, Attorneys at Law, LLP (800) 404-7770 [email protected]
